Convergence is a network of complementary service providers specializing in medicinal products & devices development, partnering to offer integrated support all along the development of your product, from global strategy to local implementation.

Find out more on www.convergence-cro.com

 

 

Convergence is:

 

A network of complementary service providers specializing in medicinal products & devices development, partnering to offer integrated support all along the development of your product, from global strategy to local implementation.

Accessing the European market is a challenge for non-European companies developing and commercializing drugs, biologics, medical devices, combination products, gene- and cell-based therapies, tissue-engineering products, or cosmetics.

Our joint holistic approach will enable you to identify strategies within the complexity of regulations at both European and national levels. We help you make the relevant and consistent choices from pre-clinical to distribution, through clinical development and health economics. Based on common scientific and therapeutic grounds, the Convergence network bridges cultural differences between EU countries towards compliance with existing regulations and anticipation of forthcoming changes.

The Drugs & Devices Convergence Research Organization is a European Network of Expertise aiming at driving the product from its design to life cycle phases.

 

Convergence members:

 

 Advanced Drug Development Services S.A.S. adds.meritnet.czAurore André, aandre@adds.com

 

Clinical development – Data management – Biostatistics – Medical writing – Risk management – Pharmacovigilance and medical device vigilance & Haemovigilance

 


Oroxcell – www.oroxcell.com – Jean Pachot, jean.pachot@oroxcell.com

 

ADME, Pharmacokinetics – Physicochemical determination – Early formulation – Stability testing and regulatory in vitro toxicology assessment

 



Porsolt & Partners – www.porsolt.com – Martine Lemaire, mlemaire@porsolt.com

 

Preclinical disease models with high translational value – Pharmacological in vivo tests and in vitro assays for (re-)profiling drugs – Safety evaluation -  from early discovery to regulatory submission (GLP)

 


Voisin Consulting Life Sciences – www.voisinconsulting.com – Emmanuelle M. Voisin. voisin@voisinconsulting.com

 

Innovative regulatory strategies – Regulatory submissions – Quality system support – Due diligence & representation of non-EU SMEs – Risk management – Pharmacovigilance, Medical device vigilance & Haemovigilance

 


LifeSci Connecting business to market – www.lifesci.biz – David Furst, david@lifesci.biz

 

Business Strategy and Implementation: Pre-market assessment, bottom-up approach – In-market presence – Market Intelligence – Distributors management & collaboration – Local implementation of marketing strategy